Drug Profile
Research programme: skin disorder therapeutics - Phio Pharmaceuticals/TransDerm
Latest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator RXi Pharmaceuticals
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders